Celldex Therapeutics, Inc.  

(Public, NASDAQ:CLDX)   Watch this stock  
Find more results for CLDX
+0.03 (0.98%)
After Hours: 3.09 0.00 (0.00%)
May 23, 6:27PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.03 - 3.11
52 week 2.85 - 5.13
Open 3.08
Vol / Avg. 0.00/1.47M
Mkt cap 384.06M
P/E     -
Div/yield     -
EPS -1.20
Shares 124.17M
Beta 2.71
Inst. own 67%
Aug 7, 2017
Q2 2017 Celldex Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 15, 2017
Celldex Therapeutics Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 9, 2017
Q1 2017 Celldex Therapeutics Inc Earnings Release
Mar 14, 2017
Q4 2016 Celldex Therapeutics Inc Earnings and Corporate Strategy Call - Webcast
Mar 14, 2017
Q4 2016 Celldex Therapeutics Inc Earnings Release
Mar 7, 2017
Celldex Therapeutics Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -2233.44% -1894.05%
Operating margin -2288.92% -1958.68%
EBITD margin - -1898.38%
Return on average assets -36.97% -35.66%
Return on average equity -53.55% -46.27%
Employees 205 -
CDP Score - -


53 Frontage Rd Ste 220
HAMPTON, NJ 08827-4034
United States - Map
+1-908-2007500 (Phone)
+1-908-4541911 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Officers and directors

Larry Ellberger Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Anthony S. Marucci President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Avery W. Catlin CPA Chief Financial Officer, Senior Vice President, Secretary
Age: 66
Bio & Compensation  - Reuters
Tibor Keler Ph.D. Executive Vice President and Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Thomas Andrew Davis M.D. Executive Vice President and Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Elizabeth Crowley Senior Vice President, Chief Product Development Officer
Age: 45
Bio & Compensation  - Reuters
Theresa M. LaVallee Ph.D. Senior Vice President - Regulatory and Precision Medicine
Age: 50
Bio & Compensation  - Reuters
Ronald A. Pepin Ph.D. Senior Vice President and Chief Business Officer
Age: 59
Bio & Compensation  - Reuters
Richard Wright Ph.D. Senior Vice President, Chief Commercial Officer`
Bio & Compensation  - Reuters
James J. Marino Esq. Director
Bio & Compensation  - Reuters